Access the full text.
Sign up today, get DeepDyve free for 14 days.
T. Geiger, M. Müller, B. Monia, D. Fabbro (1997)
Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.Clinical cancer research : an official journal of the American Association for Cancer Research, 3 7
C. Bello, L. Sherman, Jihao Zhou, L. Verkh, J. Smeraglia, J. Mount, K. Klamerus (2006)
Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjectsAnti-Cancer Drugs, 17
A. O'Farrell, J. Foran, W. Fiedler, H. Serve, R. Paquette, M. Cooper, Helene Yuen, S. Louie, Heidi Kim, S. Nicholas, M. Heinrich, W. Berdel, C. Bello, M. Jacobs, P. Scigalla, W. Manning, S. Kelsey, J. Cherrington (2003)
An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.Clinical cancer research : an official journal of the American Association for Cancer Research, 9 15
C. Britten, F. Kabbinavar, J. Hecht, C. Bello, Jim Li, C. Baum, D. Slamon (2008)
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off periodCancer Chemotherapy and Pharmacology, 61
J. Contrera, E. Matthews, N. Kruhlak, R. Benz (2004)
Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.Regulatory toxicology and pharmacology : RTP, 40 3
Y. Maruyama, M. Ono, A. Kawahara, Toshiro Yokoyama, Y. Basaki, M. Kage, S. Aoyagi, H. Kinoshita, M. Kuwano (2006)
Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis.Cancer research, 66 12
Z. Agur, L. Arakelyan, P. Daugulis, Y. Ginosar (2003)
Hopf point analysis for angiogenesis modelsDiscrete and Continuous Dynamical Systems-series B, 4
A. Oza, L. Elit, K. Swenerton, W. Faught, P. Ghatage, M. Carey, L. Mcintosh, A. Dorr, J. Holmlund, E. Eisenhauer (2003)
Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116).Gynecologic oncology, 89 1
L. Arakelyan, V. Vainstein, Z. Agur (2004)
A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growthAngiogenesis, 5
Michel Lievre, Joël Ménard, E. Bruckert, J. Cogneau, François Delahaye, Philippe Giral, Eran Leitersdorf, Gérald Luc, Luis Masana, Philippe Moulin, Philippe Passa, Denis Pouchain, Gérard Siest (2001)
Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility.BMJ : British Medical Journal, 322
Z. Agur, N. Bloch, B. Gorelik, M. Kleiman, Y. Kogan, Yael Sagi, D. Sidransky, Yael Ronen (2011)
Developing Oncology Drugs Using Virtual Patients of Vascular Tumor Diseases
David Monteith, Richard Geary, Janet Leeds, Joseph Johnston, Brett Monia, Arthur Levin (1998)
Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys.Toxicological sciences : an official journal of the Society of Toxicology, 46 2
Shin Egawa, Kazumasa Matsumoto, M. Iwamura, T. Uchida, S. Kuwao, K. Koshiba (1997)
Impact of life expectancy and tumor doubling time on the clinical significance of prostate cancer in Japan.Japanese journal of clinical oncology, 27 6
M. Cripps, A. Figueredo, A. Oza, Marianne Taylor, A. Fields, J. Holmlund, L. Mcintosh, R. Geary, E. Eisenhauer (2002)
Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 7
A. Tolcher, L. Reyno, P. Venner, S. Ernst, M. Moore, R. Geary, K. Chi, S. Hall, W. Walsh, A. Dorr, E. Eisenhauer (2002)
A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 8
(2008)
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1week off period
B. Monia, H. Sasmor, J. Johnston, S. Freier, E. Lesnik, M. Muller, T. Geiger, K. Altmann, H. Moser, D. Fabbro (1996)
Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo.Proceedings of the National Academy of Sciences of the United States of America, 93 26
Charles Rudin, J. Holmlund, G. Fleming, Sridhar Mani, Walter Stadler, Philip Schumm, Monia Bp, Johnston Jf, R. Geary, Yu Rz, Kwoh Tj, F. Dorr, M. Ratain (2001)
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 5
D. Mendel, A. Laird, Xiaohua Xin, S. Louie, J. Christensen, Guangmin Li, R. Schreck, T. Abrams, T. Ngai, Leslie Lee, Lesley Murray, J. Carver, E. Chan, K. Moss, J. Haznedar, J. Sukbuntherng, R. Blake, Li Sun, C. Tang, T. Miller, Sheri Shirazian, G. Mcmahon, J. Cherrington (2003)
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.Clinical cancer research : an official journal of the American Association for Cancer Research, 9 1
James Stevenson, K. Yao, M. Gallagher, David Friedland, Edith Mitchell, Amy Cassella, Brett Monia, T. Kwoh, Rosie Yu, Jon Holmlund, F. Dorr, Peter O'Dwyer (1999)
Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 7
K. Usuda, Y. Saito, M. Sagawa, Masami Sato, K. Kanma, Satomi Takahashi, C. Endo, Yan Chen, A. Sakurada, S. Fujimura (1994)
Tumor doubling time and prognostic assessment of patients with primary lung cancerCancer, 74
L. Arakelyan, Y. Merbl, Z. Agur (2005)
Vessel maturation effects on tumour growth: validation of a computer model in implanted human ovarian carcinoma spheroids.European journal of cancer, 41 1
B. Coudert, A. Anthoney, W. Fiedler, J. Droz, V. Diéras, M. Borner, J. Smyth, R. Morant, M. Vries, M. Roelvink, P. Fumoleau (2001)
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.European journal of cancer, 37 17
B. Gorelik, I. Ziv, R. Shohat, M. Wick, W. Hankins, D. Sidransky, Z. Agur (2008)
Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model.Cancer research, 68 21
B. Monia, J. Johnston, T. Geiger, M. Muller, D. Fabbro (1996)
Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinaseNature Medicine, 2
Yuxi Feng, F. Hagen, F. Pfister, S. Djokic, S. Hoffmann, Walter Back, Patrick Wagner, Ji-hong Lin, U. Deutsch, H. Hammes (2006)
Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpressionThrombosis and Haemostasis, 97
G. Caine, P. Ryan, G. Lip, A. Blann (2007)
Significant decrease in angiopoietin-1 and angiopoietin-2 after radical prostatectomy in prostate cancer patients.Cancer letters, 251 2
Casey Cunningham, Jon Holmlund, Schiller Jh, Richard Geary, Kwoh Tj, A. Dorr, J. Nemunaitis (2000)
A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 5
Joyce Bos (1989)
ras oncogenes in human cancer: a review.Cancer research, 49 17
V. Assikis, K. Do, S. Wen, Xuemei Wang, J. Cho-Vega, S. Brisbay, Remigio Lopez, C. Logothetis, P. Troncoso, C. Papandreou, T. McDonnell (2004)
Clinical and Biomarker Correlates of Androgen-Independent, Locally Aggressive Prostate Cancer with Limited Metastatic PotentialClinical Cancer Research, 10
The decreasing cost-efficiency of drug development threatens to result in a severe shortage of innovative drugs, which may seriously compromise patient healthcare. This risk underlines the urgency to change the paradigm in clinical research. Here, we examine a novel concept of conducting virtual clinical trials for efficiently screening drug candidates, and for evaluating their prospects of being brought to the market successfully. The virtual clinical trials are carried out by using virtual patients (denoted Optimata Virtual Patients — OVPs). The OVP, a set of mathematical algorithms that describe the main pathological and physiological dynamic processes affected by the administered drug, has been shown to accurately predict docetaxel efficacy and safety in individual breast cancer patients. We report a test case in which virtual clinical trials have been conducted by using OVP populations for rescuing a discontinued oncology compound, ISIS-5132 (ISIS Pharmaceuticals Inc.). Our in silico study suggested that ISIS-5132 may be efficacious in combination with another drug, sunitinib malate (Sutent®, Pfizer Inc.), for the treatment of prostate cancer. The recommended combined treatment is predicted to result in a higher five-year Progression-Free Survival than monotherapy with either drug alone.
Alternatives to Laboratory Animals – SAGE
Published: Sep 1, 2009
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.